Fluidigm Corporation Release: New Single-Cell Whole Genome Sequencing Workflow Allows Discovery Of Novel Cellular Heterogeneity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today announced a new single-cell application for its C1TM system that improves whole genome sequencing of individual cells. Single-cell whole genome sequencing allows researchers to explore mutations in regulatory and protein coding regions of the genome in order to identify novel signatures within heterogeneous cell populations. This application will empower cancer researchers to discover and define specific mutation profiles to predict cancer susceptibility, metastasis, and therapeutic efficacy.
“It is essentially impossible to understand the distribution of mutations, rearrangements and copy number changes among cells through bulk sequencing,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. “We have made single-cell DNA sequencing accessible, and believe that this can usher in a whole new phase of discovery in single-cell biology.”
Help employers find you! Check out all the jobs and post your resume.
“It is essentially impossible to understand the distribution of mutations, rearrangements and copy number changes among cells through bulk sequencing,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. “We have made single-cell DNA sequencing accessible, and believe that this can usher in a whole new phase of discovery in single-cell biology.”
Help employers find you! Check out all the jobs and post your resume.